Literature DB >> 7684350

Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically.

K Norrby1.   

Abstract

The systemic effect of 2.4-, 8-, 15- and 22-kDa heparin fractions on saline-mediated angiogenesis in rats was compared with the systemic effect of an unfractionated Na-standard heparin (UFH), which had a mean molecular weight of about 15 kDa. Using the mesenteric-window assay in adult rats, the relative vascularized area was quantified morphometrically. The angiogenic response was strictly related to the mean molecular weight of the saccharides (r = 0.97); the 2.4-kDa fraction suppressed angiogenesis by 46% (p < or = 0.001), whereas the 22-kDa fraction stimulated angiogenesis by 123% (p < or = 0.01), as compared with the UFH. The UFH, thus, contained chain-length-related fragments that induced systemic antiangiogenic and angiogenic activity.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7684350     DOI： 10.1159/000216923

Source DB:  PubMed          Journal:  Haemostasis        ISSN： 0301-0147


  16 in total

1.  In vivo treatment of rats with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) does not affect experimentally induced colon carcinoma metastasis.

Authors:  S M Smorenburg; R Vink; M te Lintelo; W Tigchelaar; A Maas; H R Büller; C J van Noorden
Journal:  Clin Exp Metastasis       Date:  1999-07       Impact factor: 5.150

2.  A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity.

Authors:  Hidenori Takahashi; Satoru Ebihara; Tatsuma Okazaki; Masanori Asada; Hidetada Sasaki; Mutsuo Yamaya
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

3.  2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165-mediated mammalian angiogenesis.

Authors:  K Norrby
Journal:  Int J Exp Pathol       Date:  2000-06       Impact factor: 1.925

4.  Mast cell and macrophage counts and microvessel density in invasive breast carcinoma-comparison analysis with clinicopathological parameters.

Authors:  Gui Young Kwon; Sang Dae Lee; Eon Sub Park
Journal:  Cancer Res Treat       Date:  2005-04-30       Impact factor: 4.679

5.  The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model.

Authors:  I Debergh; N Van Damme; P Pattyn; M Peeters; W P Ceelen
Journal:  Br J Cancer       Date:  2010-02-02       Impact factor: 7.640

6.  Determining the anti-coagulant-independent anti-cancer effects of heparin.

Authors:  V Solari; E C Jesudason; J E Turnbull; E A Yates
Journal:  Br J Cancer       Date:  2010-07-20       Impact factor: 7.640

7.  The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer.

Authors:  Jong Chul Park; Caroline F Pratz; Anteneh Tesfaye; Robert A Brodsky; Emmanuel S Antonarakis
Journal:  Clin Genitourin Cancer       Date:  2014-06-11       Impact factor: 2.872

Review 8.  Cancer and thrombosis: mechanisms and treatment.

Authors:  Steven R Deitcher
Journal:  J Thromb Thrombolysis       Date:  2003 Aug-Oct       Impact factor: 2.300

9.  Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial.

Authors:  H Ian Robins; Anne O'Neill; Mark Gilbert; Mark Olsen; Ronald Sapiente; Brian Berkey; Minesh Mehta
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-20       Impact factor: 3.333

Review 10.  The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.

Authors:  Andrew D Blann; Chee W Khoo
Journal:  Vasc Health Risk Manag       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.